Medicap Healthcare IPO

Medicap Healthcare IPO Details

Medicap Healthcare IPO is a 100% book-built, offering a fresh issue worth up to ₹240 crore with a face value of ₹10 per share. The company filed its DRHP with SEBI on Sep 22, 2025.

The price band and official dates of listing and subscription will be announced by the company later, but the equity shares are intended to be listed on the BSE and the NSE platforms. The book-running lead manager for this issue is Aryaman Financial Services Ltd., while the registrar to the issue is Kfin Technologies Ltd.

Medicap Healthcare IPO Date & Timeline

Medicap Healthcare Ltd.’s DRHP was filed with SEBI on September 22, 2025. The company received the approval letter from SEBI on January 23, 2026. As of now, the Medicap Healthcare IPO for the opening and closing dates of the issue has not been fixed and will be announced by the company later via its lead manager.

Medicap Healthcare IPO GMP (Grey Market Premium)

“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.

The Medicap Healthcare IPO GMP is currently trading at ₹[.], reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹[.], which is [.]% above the issue price. While the Grey Market Premium (GMP) is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.

Company Background

Medicap Healthcare Ltd. was founded as a partnership firm under the name Medicap Inc. in 2014. The company was transformed into a public limited company, incorporated as Medicap Healthcare Limited, on June 2, 2017. The company operates as a limited company and is located in Vadodara, Gujarat. It has transformed itself from trading in pharmaceuticals to establishing a strong base in manufacturing.

The company now primarily deals in the production of specialized, high-precision packaging components for the healthcare and personal hygiene industry. The company has managed to grow from a regional base to become a known entity in the domestic pharmaceutical packaging supply chain.

Operations & Product Range

Medicap Healthcare Ltd. is in the niche market of pharmaceutical packaging manufacturing. Its core activity is to specialize in making highly accurate packaging parts, which are of utmost importance in safely containing pharmaceutical products. Some of their products include special Euro head caps, which are commonly used in IV fluid containers.

They also specialize in closures and bottle performances, while their target market includes large and mid-sized pharmaceutical companies that need contamination-free packaging solutions. By maintaining high levels of manufacturing hygiene, they can easily integrate into the operational supply chains of their B2B pharmaceutical clients.

Facilities & Capacity

Medicap Healthcare Ltd. has its operational infrastructure in place at its modern manufacturing facility located in the GIDC Manjusar area of Vadodara, Gujarat. The facility, covering an area of approximately 6,732 square meters, has advanced technology installed to carry out the manufacture of pharmaceutical packaging materials. The operational capacity is to be enhanced by adding approximately 966 million units annually for its Euro Head Caps and Preforms lines. The acquisition of a 51% stake in KASR Healthcare has enhanced operational facilities in the manufacture of IV fluids.

Brands & Market Presence

Medicap Healthcare Ltd. operates as a B2B brand and has managed to develop a favorable market presence as a supplier in the pharmaceutical packaging industry. The company has a substantial domestic presence, as it derives about 80% of its overall revenues from the Indian market, as its offerings are used as infrastructure for various medical formulations. The company has managed to diversify its business by actively participating in the export market, which contributes the remaining 20%. The adherence to strict manufacturing standards guarantees it the operational credibility required for the export market.

Revenue Streams & Business Model

Medicap Healthcare Ltd. primarily earns revenue from the large-scale production and subsequent sales of specialized pharmaceutical packaging products. Operating entirely on a B2B business model, the company primarily depends on building long-term business relationships with pharmaceutical companies.

The business model of Medicap is the high retention rate of clients, with the company consistently earning more than 90% of its revenue from repeat business. The primary source of revenue is domestic sales, with the company's export business serving as a supplementary source of income.

Management & Shareholding

The promoter group at Medicap Healthcare Ltd. comprises the management team, which oversees the execution process. The major promoters include Kamalkumar Aggarwal, Rajveer Kamal Aggarwal and Minal Aggarwal. Before the IPO, the company's shareholding pattern showed that the promoter group had a 98% majority shareholding. However, after the IPO, the shareholding pattern changes and the promoters have a majority shareholding, indicating that leadership continuity is ensured for the company.

Board & Key Management

The organizational strategy of Medicap Healthcare Ltd. is overseen by professional members of the board. The promoters are actively involved in executive leadership roles, which means they are responsible for running the business daily. To ensure strict corporate governance, the board includes non-executive independent directors, such as Neel Shah, providing objective oversight. The financial strategy is guided by CFO Mayur Jitendra Thakar, who aligns the fiscal management with the broader expansion goals outlined in the DRHP.